Telix Pharmaceuticals Ltd (TLX)

Sydney
Currency in AUD
Disclaimer
11.040
-0.360
(-3.16%)
Closed
Day's Range
11.040
11.530
52 wk Range
4.745
12.790
Volume
795,700
Bid/Ask
11.040 / 11.050
Prev. Close
11.4
Open
11.22
Day's Range
11.04-11.53
52 wk Range
4.745-12.79
Volume
795,700
Average Volume (3m)
1,152,456
1-Year Change
143.02%
Shares Outstanding
319,976,158
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
1,202.675
Upside +10,793.795%

People Also Watch

1.775
CRN
-4.57%
8.17
360
-2.27%
4.38
CHPT
-7.89%
13.92
MND
-0.36%
7.20
MAD
+8.11%
How do you feel today about TLX?
Vote to see community's results!
or

Telix Pharmaceuticals Ltd Company Profile

Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic radiopharmaceuticals products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. The Company’s lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.

Income Statement